Transcriptome-(Phospho)proteome Characterization of the Brain of a Constitutional Model of Cytoplasmic-predominant Pten Expression With Autism-Like Phenotypes

Stetson Thacker  
Cleveland Clinic  https://orcid.org/0000-0001-6050-409X

Charis Eng (engc@ccf.org)  
Case Western Reserve University School of Medicine  https://orcid.org/0000-0002-3693-5145

Research

Keywords: PTEN, PSD-95, autism spectrum disorder, proteome, phosphoproteome, transcriptome, mouse model, network analysis

DOI: https://doi.org/10.21203/rs.3.rs-111823/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

PTEN, a well-studied tumor suppressor, has one of the strongest Mendelian associations with autism spectrum disorder (ASD), representing a special case in autism's complex genetic architecture. Animal modeling for constitutional Pten mutation creates an opportunity to study how disruption of Pten affects neurobiology, providing insights that may be generalizable or at least inform our understanding of ASD. Although the neural transcriptome has been well characterized in Pten models, little has been done concerning the proteome and phosphoproteome. This is a critical gap in knowledge given that these –omic landscapes are more proximal to the actively observed biology than the transcriptome.

Methods

We sought to comprehensively characterize the neural proteome and phosphoproteome of the Ptenm3m4/m3m4 mouse, which exhibits cytoplasmic-predominant Pten expression. Proteomic and phosphoproteomic scans of Ptenm3m4/m3m4 and wildtype mouse brain at two-weeks- (P14) and six-weeks-of-age (P40) were performed using liquid chromatography with tandem mass spectrometry technology. Following quantification of differentially expressed/phosphorylated proteins, we performed gene overlap, gene enrichment, pathway, and network analyses to identify the similarity across the various datasets and understand the affected biological landscape.

Results

We identified numerous differentially expressed/phosphorylated proteins, finding that dysregulation was greater at P40, consistent with the prior neural transcriptome data. We found the affected biological pathways were largely related to PTEN function, neurological processes, or neuroinflammation. Although we found minimal overlap among differentially expressed transcriptome-proteome-phosphoproteome molecules between P14 and P40 brains, there was congruence amongst the affected pathways. Importantly, network analysis identified Pten and Psd-95 as predominant regulatory nodes in the proteome and phosphoproteome, respectively. Moreover, we found overlap between our differentially expressed/phosphorylated proteins and known ASD risk genes.

Conclusions

Differential expression/phosphorylation revealed by transcriptome-proteome/phosphoproteome analyses of a germline Pten mutation model point to ASD risk genes like Pten and Psd-95 as major hubs in the protein networks, highlighting their important regulatory influence. Our observations here suggest Pten and Psd-95, known interactors in biological networks in the brain, are critical to either initiation or maintenance of cellular and perhaps organismal phenotypes related to ASD. Future research should explore rescuing Pten and Psd-95 function in attempts to ameliorate neurological pathologies and behavioral abnormalities.

Background

PTEN (Phosphatase and Tensin homolog on chromosome Ten, OMIM #601728), a well-studied, tumor suppressor gene, is known for its canonical role as the major antagonist of PI3K/AKT/mTOR signaling, a crucial growth and survival intracellular cascade, via the lipid modality of PTEN’s dual-specific phosphatase function.
Germline \textit{PTEN} mutations are considered a rare cancer predisposition mechanism, while also representing one of the strongest Mendelian associations with autism spectrum disorder (ASD) \cite{4,5}. Ostensibly, individuals with germline \textit{PTEN} mutations present with a diverse array of clinical phenotypes, ranging from high risk of benign and malignant neoplasia to ASD \cite{6}.

Next-Generation Sequencing (NGS) technology has gifted biomedical science a tool for exploration of big data, especially for complex diseases like ASD. While there have been several rigorous efforts to explore the transcriptome of ASD \cite{7–14}, there has been a limited exploration of the proteome of ASD \cite{15–19}. Little has been done to understand the proteome, let alone characterize the functional effectors of the phosphoproteome in syndromic ASD contexts, such as those arising from Mendelian gene variation, here, germline \textit{PTEN} mutation. Thus, we believe that animal modeling for \textit{PTEN} mutation-associated ASD followed by the deployment of proteomic/phosphoproteomic technologies could represent an excellent approach for disentangling the complexity associated with autism pathophysiology.

Given the prior findings from the \textit{Pten}^{m3m4} mouse and the lack of neural (phospho)proteomic data available to interrogate \textit{PTEN} pathophysiology in the context of ASD, we performed proteomic, phospho-serine/threonine (pS/pT) proteomic, and phospho-tyrosine (pY) proteomic surveys of two-week-old (P14) hemibrains and six-week-old (P40) cortices of \textit{Pten}^{m3m4/m3m4} mice compared to littermate wildtype samples. We hypothesized that disruption of Pten, which has poorly characterized but likely promiscuous protein phosphatase function, would likely perturb the phosphoproteome in ways that contribute to pathophysiology that disrupts synaptic functions and promotes stress or neuroinflammatory processes. Furthermore, we anticipated disruption of the proteome given the previously documented changes in the transcriptome and anticipated relationships between the differential expression in the transcriptome and proteome. Ultimately, our transcriptome-proteome-phosphoproteome exploration of the molecular complexity of the \textit{Pten}^{m3m4} brain has illuminated the variation within and between different –omic landscapes, identifying important candidate regulators and effectors of \textit{PTEN} dysfunction in human ASD.

\section*{Methods}

\subsection*{The \textit{Pten}^{m3m4} murine model}

Our planned experimental procedures were approved by the Cleveland Clinic's Institutional Animal Care and Use Committee (IACUC) under protocol numbers 2018-1952 and 2017-1879 and guided by the Principles of Laboratory Animal Care formulated by the National Society for Medical Research. We created the \textit{Pten}^{m3m4} mouse on an outbred CD1 background, which has been studied extensively, shown to have deficits in social behavior, changes in neuron and glia populations, and changes in gene expression in many known autism risk genes \cite{21–23,25,26,29}. The \textit{Pten}^{m3m4} mutation, located within exon 7 of mouse \textit{Pten}, consists of five nucleotide substitutions that results in four nonsynonymous and one synonymous codon changes. The four missense mutations disrupt the third (m3) and fourth (m4) putative nuclear localization-like sequences of Pten \cite{20,21}. We performed mouse genotyping on genomic DNA extracted from toe clippings following Jackson Laboratory's protocol using in-house PCR primers. The wildtype allele primers are mPten-F5, 5'-TGGCAGACTCTTTCTTTCTGTCG-3', and mPten-R6, 5'-ACTTCTTCAACACACTTACTCTTTCAAC-3', and mutant allele primers are mPten-F3, 5'-TACCCGGAATTTCAGACAGAC-3', and mPten-R6, 5'-
ACTTCTTCAACAACCCTTTCTTTCAAC-3′. Our mice were maintained on a 14:10 light:dark cycle, where access to food and water was *ad libitum*. We maintained room temperature between 18 and 26°C. Mice were euthanized via CO2 asphyxiation with additional cervical dislocation. None of the experiments were blinded but all were randomized and conducted under protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Cleveland Clinic. In our experiments, we utilized only male mice because the  *Pten*  behavioral phenotypes are most pronounced in males, and the previous RNA-Seq experiment used only male mice [25,26]. A sample size of three biological replicates (N = 3) was used for each genotype and each time point of the study.

**Transcriptomic data analysis**

The hemibrain and cortical transcriptome of two-week-old and six-week-old  *Pten*  mice (GSE59318), respectively, shares a similar differential expression (DE) profile with that of idiopathic autism, as described in detail by Tilot et al [25]. We deployed Ingenuity Pathway Analysis (IPA) software (Qiagen, Redwood City, California) to perform a core analysis on the DE genes from the hemibrain and cortex of  *Pten*  homozygous mutant and wild-type mice at both time points (i.e. P14 and P40). We also confirmed and extended this analysis with STRING software (version 11.0; [https://string-db.org/](https://string-db.org/)). We performed STRING analysis on the same list of DE. These comparisons were of the homozygous mutant compared to the wildtype (i.e., MUT versus WT = MUT/WT Fold Change).

**Proteomic scan**

Three wildtype and three homozygous mutant two-week-old mouse hemibrains and three wildtype and three homozygous mutant six-week-old cortices were submitted to the Lerner Research Institute (LRI) Proteomics Core. These samples were homogenized in urea lysis buffer (20mM HEPES, 9M urea, 1X HALT phosphatase inhibitor, pH 8.0) with lysis Matrix D beads using FastPrep-24 from MP Biomedical. An aliquot from each tissue lysate was taken out for in-solution tryptic digestion. These samples were solubilized in 50 μL of in-solution digestion buffer, 6M urea, 100 mM Tris pH 8.0, reduced with DTT, alkylated with iodoacetamide, and then diluted to give a final urea concentration of less than 1 M for digestion. All samples were digested in-solution by adding 0.5 μg trypsin and incubating overnight at room temperature. A second aliquot of trypsin was added and digestion was continued for an additional 6 hours. After digestion, the peptides were desalted and quantified using Thermo Scientific Pierce Quantitative Colorimetric Peptide Assay kit (Thermo Scientific #23275). A 100 μg peptide aliquot from each sample was dried down and reconstituted in 100 μL 20 mM ammonium formate (pH 10) for offline fractionation. Fractionation was performed by loading 90 μL onto an offline Hp-RP separation column (Waters, XBridge C18 3.5 μm, 2.1 × 100 mm, or Waters XBridge C18 3.5 μm, 2.1 × 150 mm) using an Agilent 1200 microflow pump. The samples were fractionated using a stepwise gradient at 250 μL/min for 40min. A fraction collector was used for collection with a rate of 1 minute per fraction through the rest of the gradient. One of every four collections were combined and a total of 10 fractions per sample was obtained. Each combined fraction was lyophilized by vacuum centrifugation, and reconstituted in 30 μL 1% acetic acid for LC-MS/MS. The LC-MS system was a Finnigan LTQ-Obitrap Elite hybrid mass spectrometer system. The HPLC column was a Dionex 15 cm x 75 μm id Acclaim Pepmap C18, 2μm, 100 Å reversed phase capillary chromatography column. Five μL volumes of the extract were injected and the peptides eluted from the column by an acetonitrile/0.1% formic acid gradient at a flow rate of 0.25 μL/min were introduced into the source of the mass spectrometer online. The microelectrospray ion source is operated at 2.5 kV. The digest was analyzed using the data dependent...
multitask capability of the instrument acquiring full scan mass spectra to determine peptide molecular weights and product ion spectra to determine amino acid sequence in successive instrument scans. The data was analyzed by using all CID spectra collected in the experiment to search the mouse UniProtKB databases with the search program Mascot and Sequest. These search results were then uploaded into the program Scaffold. The quantitation was performed by comparing the normalized spectral counts for these samples. The experimental comparison is between homozygous mutant and wildtype (i.e., MUT versus WT = MUT/WT Fold-Change).

**Phospho-serine/threonine proteomic scan**

Three wildtype and three homozygous mutant two-week-old mouse hemibrain and three wildtype and three homozygous mutant six-week-old cortices were submitted to the Lerner Research Institute (LRI) Proteomics Core. These samples were homogenized in urea lysis buffer (20mM HEPES, 9M urea, 1X HALT phosphatase inhibitor, pH 8.0) with lysis Matrix D beads using FastPrep-24 from MP Biomedical (Solon, OH). The protein concentration was measured using a Pierce BCA assay kit. The proteins samples were reduced with DTT and alkylated with iodoacetamide. These proteins were then digested with trypsin overnight at room temperature. After digestion, the peptides were purified using Sep-Pak C18 spin columns (Waters Corporation, WAT 051910). Prior to enrichment, an 8 pmol aliquot of phosphopeptide standard mix was spiked into each sample. Phosphopeptide enrichment was performed using Pierce TiO2 Phosphopeptide Enrichment Spin Tips according to the manufacturer's instructions. The enriched peptide samples were subjected to C18 clean-up prior to LC-MS/MS analysis. The LC-MS system was a ThermoScientific Fusion Lumos mass spectrometry system. The column was a Dionex 15 cm x 75 μm id Acclaim Pepmap C18, 2μm, 100 Å reversed-phase capillary chromatography column. Five μL volumes of the extract were injected and the peptides eluted from the column by an acetonitrile/0.1% formic acid gradient at a flow rate of 0.25 μL/min were introduced into the source of the mass spectrometer on-line. The microelectrospray ion source is operated at 1.9 kV. The digest was analyzed using the data dependent multitask capability of the instrument acquiring full scan mass spectra to determine peptide molecular weights and product ion spectra to determine amino acid sequence in successive instrument scans. The data were analyzed by using all CID spectra collected in the experiment to search the mouse UniProtKB databases with the programs Proteome Discoverer 2.2. The experimental comparison is between homozygous mutant and wildtype (i.e., MUT versus WT = MUT/WT Fold Change).

**Phospho-tyrosine proteomic scan**

Three wildtype and three homozygous mutant hemibrain and cortical tissue samples from P14 and P40 mice was delivered to the Proteomics Services Group, Cell Signaling Technology (Danvers, MA). These samples were homogenized and subject to protease digestion yielding peptides. These extracted peptides were loaded directly onto a 50 cm x 100 μm PicoFrit capillary column packed with C18 reversed-phase resin. The column was developed with a 90-minute linear gradient of acetonitrile in 0.125% formic acid delivered at 280 nL/min. After C18 solid phase extraction, the peptides were enriched for phospho-Y residue by immunoprecipitation using a phosphotyrosine pY-1000 motif antibody (CST #8954) on A/G beads. After immunoprecipitation the resin was washed, the phosphopeptides were eluted, and then analyzed by LC-MS/MS using Orbitrap-Fusion Lumos, ESI-HCD. The MS analysis was performed with the following parameters: MS Run Time 96 min, MS1 Scan Range (300.0 – 1500.00), Top 20 MS/MS (Min Signal 500, Isolation Width 2.0, Normalized Coll. Energy 35.0, Activation-Q 0.250, Activation Time 20.0, Lock Mass 371.101237, Charge State Rejection Enabled, Charge State 1+ Rejected, Dynamic Exclusion Enabled, Repeat Count 1, Repeat Duration 35.0, Exclusion List Size 500, Exclusion
Duration 40.0, Exclusion Mass Width Relative to Mass, Exclusion Mass Width 10ppm). MS/MS spectra were evaluated using SEQUEST. Searches were performed against the most recent update of the Uniprot *Mus musculus* database with mass accuracy of +/-50 ppm for precursor ions and 0.02 Da for product ions. Results were filtered with mass accuracy of +/- 5 ppm on precursor ions and presence of the intended motif. The experimental comparison is between homozygous mutant and wildtype (i.e., MUT versus WT = MUT/WT Fold Change).

**Bioinformatic analysis**

In order to assess the biology impacted by the differential expression or differential phosphorylation observed in our various –omic datasets, we employed Ingenuity Pathway Analysis (IPA, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)) to perform core analysis, which provides enrichment scores as p-values for their various outputs (e.g. canonical pathways) determined by one-tailed Fisher's exact test using Ingenuity Knowledge Base as a reference (restricted to only experimentally observed findings on the *mus musculus* background). Reported p-values were adjusted for multiple-testing using Benjamini-Hochberg (BH) procedure. We also used STRING software ([https://string-db.org/](https://string-db.org/)) to obtain gene ontology, Reactome ([https://reactome.org](https://reactome.org)), and KEGG results. The STRING analysis served to both confirm the observation in IPA, which are based on a proprietary database, and to obtain the raw data to pass along to network analysis.

**Network analysis**

We performed network analysis using Cytoscape 3.7.0 ([https://cytoscape.org/](https://cytoscape.org/)) on the interaction data generated by STRING software ([https://string-db.org/](https://string-db.org/)) on all of our –omic datasets. The STRING analysis generates an association network from an input gene list based on their database of biological relationships, which included several types of evidence: co-expression, text-mining, biochemical/genetic data, and previously curated pathway and protein-complex knowledge. Cytoscape 3.7.0 was utilized to generate the network figures and statistics, such as degree connectivity and betweenness centrality.

**Results**

**Differential expression and phosphorylation in *Pten*\(^{m3m4}\) brain**

In order to assess how the m3m4 mutation affects the landscape of gene and protein expression and protein phosphorylation, we performed parallel transcriptomic [25], proteomic, and phosphoproteomic experiments on *Pten*\(^{m3m4/m3m4}\) hemibrains and cortices at two-weeks- (P14) and six-weeks-of-age (P40), respectively (Fig. 1a). At P14, a total of 3,207 unique proteins, with an average of 2,345 unique proteins per sample, were identified (Additional file 1: Table S1), whereas at P40, a total of 6,635 unique proteins, with an average of 5,381 unique proteins per sample, were identified (Additional file 1: Table S2). Principal component analysis (PCA) based on the LFQ/NSAF abundance values for a given protein, at both time points revealed completely separate clusters representing homozygous mutant and wildtype samples (Additional file 2: Fig. S1A, B). At P14, a total of 4,080 unique peptides were identified, 97% of which contained phosphorylated residues in the phospho-serine/threonine scan, an average of 2,239 unique phosphopeptides per sample (Additional file 1: Table S3). At P40, a total of 8,468 unique peptides were identified, 90% of which contained phosphorylated residues, with an average of 5,783 unique phosphopeptides per sample (Additional file 1: Table S4). PCA, based on the LFQ
abundance values for a given phosphopeptide, at both time points revealed non-overlapping clusters of homozygous mutant and wildtype samples (Additional file 2: Fig. S1C, D). These findings illustrate robust sampling of the proteome and phosphoproteome, and the captured variability differentiated homozygous mutant and wildtype brain samples well.

In assessing differentially expressed proteins, we found 24 over-expressed and 27 under-expressed proteins in the P14 mutants compared to wildtype controls (Table 1; Fig. 1b). At P40, we identified 150 over-expressed and 102 under-expressed proteins in the mutant brains compared to the wildtype brains (Table 1; Fig. 1b). When assessing differential phosphorylation of phospho-serine/threonine phosphopeptides, we found 1 increased and 99 decreased in the P14 mutant hemibrain (Table 1; Fig. 1c). Moreover, we found 113 increased and 185 decreased at P40 in the mutant cortex (Table 1; Fig. 1c). In the special phospho-tyrosine-specific phospho-scan, we identified 39 and 29 relatively increased phosphopeptides at P14 and P40, respectively (Table 1). In the same phospho-tyrosine scan, we found 29 and 26 decreased phosphopeptides at P14 and P40, respectively (Table 1). Overall, the over-expression/under-expression of proteins or enrichment/depletion of phosphopeptides were distributed roughly equally except in the P14 phospho-serine/threonine scan, where phosphopeptide depletion was heavily favored in the mutant by 99-fold (Table 1). Moreover, there is a general increase in differential expression and phosphorylation as the $Pten^{m3m4/m3m4}$ mice age, a trend not observed in the phospho-tyrosine scan (Table 1).

**Dissimilarity across –omic datasets describing the $Pten^{m3m4}$ brain**

Given the eight different –omic datasets spanning two time points, we sought to understand what molecules, showing differential expression/phosphorylation in the homozygous mutant brain, were shared among these datasets. Thus, we performed pairwise comparisons of the molecule lists of each separate –omics approach that compared $Pten^{m3m4/m3m4}$ to $Pten^{+/+}$ mice for both P14 and P40 time points. Surprisingly, we found no intersection between the P14 and P40 proteome (Fig. 2a). For the phospho-serine/threonine scan, we found 21 molecules or roughly 7% of all input molecules shared between time points (Fig. 2b). For the phospho-tyrosine scan, we found 25 molecules or roughly 32% of all input molecules shared between time points (Fig. 2c). Furthermore, 49 molecules were shared between the P14 and P40 transcriptome datasets or roughly 4% of all input molecules (Fig. 2d). These analyses indicate little to marginal overlap within the various –omic scans over developmental time.

Additionally, we assessed overlap among the proteomic and phosphoproteomic datasets within their respective time points. Surprisingly, we found almost no intersection across these datasets (Fig. 2e). We proceeded to assess the overlap between the transcriptome and proteome within each time point and found 1 and 30 intersecting molecules at P14 and P40, respectively (Fig. 2f). Although we expected to find more shared genes between the transcriptome and proteome, these observations suggest that the mechanisms governing changes in protein expression are separate from those governing gene expression in our model. Moreover, the general lack of overlap among the various datasets suggests that in the context of Pten disruption, there may be little redundancy in modes of dysregulation, meaning that molecules are either subject to dysregulation via expression or phosphorylation but not both.

**Differentially expressed/phosphorylated molecules associate with major intracellular signaling cascades, neurological processes, and cancer**
To understand the biological consequences of the observed changes in protein expression and phosphorylation in the \( \text{Pten}^{m3m4/m3m4} \) cortex, we performed an IPA analysis on the proteomic and phosphoproteomic (pooled phospho-serine/threonine and phospho-tyrosine datasets) findings. The comprehensive summaries for all IPA analyses can be found in the supplemental information (Additional file 3). The top five most enriched canonical pathways at P14 and P40 for the proteome and phosphoproteome are shown in Fig. 3a and b, respectively. In the \( \text{Pten}^{m3m4/m3m4} \) proteome, the top implicated canonical pathways broadly involve phosphoinositide metabolism (i.e., \( 3'-\text{phosphoinositide Biosynthesis} \)) or neurological pathways, such as GABA Receptor Signaling (Fig. 3a). In the \( \text{Pten}^{m3m4/m3m4} \) phosphoproteome, the top implicated canonical pathways generally involve neurological and cancer processes or major cellular signaling cascades: Molecular Mechanisms of Cancer, Synaptic Long Term Potentiation, and cAMP-mediated Signaling (Fig. 3b). Moreover, we extracted the top two salient disease and bio function networks (i.e., the networks comprised of the largest number of differentially expressed/phosphorylated molecules) from the proteome and phosphoproteome at P40. Cancer and Development of Head are the two largest disease and bio function networks identified by IPA in the \( \text{Pten}^{m3m4/m3m4} \) P40 cortical proteome (Fig. 3c), and Synaptic Transmission and Seizure Disorder are two of the largest salient networks from the \( \text{Pten}^{m3m4/m3m4} \) P40 cortical phosphoproteome (Fig. 3d). These enrichment analyses highlight the broad yet related biological perturbations in the neural (phospho)proteome of \( \text{Pten}^{m3m4/m3m4} \) mice.

In an effort to understand more about how these biological changes are initiated and maintained, we sought to identify important upstream regulators via network analysis of the differentially expressed proteins. Strikingly, the top protein interaction network identified by IPA from the \( \text{Pten}^{m3m4/m3m4} \) P40 cortical proteome agnostically positions Pten as the pre-eminent regulatory node via hierarchical ordering. The position of Pten at the top of this network's regulatory architecture establishes its importance and influence as a regulator of the molecules positioned below (Fig. 3e). When IPA's biological predictions are overlaid on the network using the Molecule Activity Predictor (MAP) tool, the observed decrease in Pten expression predicts an increase in the activity of Pi3k, Akt, Erk, p70 S6, Gfap, and C1qa, while predicting a decrease in P38 Mapk and Creb (Fig. 3e). These predictions are largely consistent with previous observations in the \( \text{Pten}^{m3m4/m3m4} \) cortex [21,23,24]. The network analysis enables a biological understanding of the changes in protein expression and phosphorylation, which unequivocally point to disrupted Pten function in the brain and highlight its importance in propagating dysfunction to downstream effector molecules.

**Pten and Psd-95 are major regulatory nodes in the \( \text{Pten}^{m3m4/m3m4} \) cortex**

In an effort to expand our biological understanding of the results from the proteomic and phosphoproteomic \( \text{Pten}^{m3m4/m3m4} \) versus \( \text{Pten}^{+/+} \) comparisons, we performed STRING analyses on each to identify the relationships among the differentially expressed/phosphorylated molecules. We extracted the largest STRING networks from each -omic dataset at each time points and analyzed the network statistics using Cytoscape (Additional file 2: Fig. S2). The most striking network findings were observed in the P40 \( \text{Pten}^{m3m4/m3m4} \) cortical proteome and phosphoproteome. In the largest network (83 nodes) constructed from the P40 \( \text{Pten}^{m3m4/m3m4} \) cortical proteome findings, we found that Pten exhibited the greatest degree of connectivity, 12, and betweenness centrality, 0.66, relative to all other nodes (Fig. 4a). These data independently identify Pten as the most connected (i.e., degree connectivity) and most important node for transmitting information across the network (i.e., betweenness centrality), suggesting that Pten is likely to be the dominant regulatory node affecting...
the network of differentially expressed proteins in the P40 mutant cortex. Additionally, in the largest network (92 nodes) constructed from the P40 $Pten^{m3m4/m3m4}$ cortical phospho-serine/threonine scan, we found Psd-95 (also known as Dlg4) exhibited the greatest degree connectivity, 19, and betweenness centrality, 0.68, relative to all other nodes (Fig. 4b). These data identify Psd-95 as the most connected (i.e., highest degree connectivity) and most important node for transmitting information across the network (i.e., highest betweenness centrality), suggesting that Psd-95 is likely to be the dominant regulatory node affecting the network of differentially phosphorylated proteins in the P40 mutant cortex. The Psd-95 finding also implicates Pten given the known and well-described protein-protein relationship between the two [30]. Ultimately, the STRING network analysis implicates Pten and Psd-95 as the likely perpetrators of the proteomic and phosphoproteomic dysregulation observed in the cortex of the $Pten^{m3m4/m3m4}$ model and possibly responsible for some of the pathological cellular, physiological, and behavioral phenotypes.

**Meaningful overlap between differentially expressed or phosphorylated molecules and known ASD risk genes**

We sought to assess whether the differentially expressed/phosphorylated molecules identified by our –omic surveys demonstrate significant overlap with known autism risk genes as curated by the Simons Foundation Autism Research Initiative (SFARI). Accordingly, we compared the SFARI catalogue of ASD risk genes with the gene lists of the significant results of –omic surveys (time points and phospho-serine/threonine/tyrosine pooled). We found that 41 molecules intersected between the phosphoproteome and SFARI genes, and 12 molecules intersected between the proteome and SFARI (Fig. 5a). This was modest overlap given the number of genes curated by SFARI, but again, STRING network analysis implicated Pten and Psd-95 as central nodes in association networks derived from the intersecting molecules (Fig. 5b, c). The re-emergence of Pten and Psd-95 in a separate network analysis predicated on known ASD risk genes strengthens the evidence that implicates them as potential drivers of the phenotypes observed in $Pten^{m3m4/m3m4}$ mouse model. The overlap that does exist with the known ASD risk genes underscores the importance of Pten biology to ASD pathophysiology overall.

**Discussion**

This study represents a proteomic and phosphoproteomic exploration of the brain of a Pten model with strong neurological phenotypes. These experiments demonstrate a distinct developmental difference in protein expression and phosphorylation with differences of greater number, magnitude, and significance at P40 versus P14 (Fig. 1). We found little to marginal overlap among the various –omic datasets; interestingly, however, the affected biological pathways across the different datasets were similar, if not overlapping (Fig. 2, 3), suggesting potential convergence of non-overlapping, non-redundant regulatory mechanisms. Furthermore, network analysis highlighted Pten as a critical regulator of the differential expression observed in the neural proteome (Fig. 3e, 4a), and Psd-95 as a critical regulator of differential phosphorylation observed in the neural phosphoproteome (Fig. 4b). Ultimately, we observed overlap between our agnostic survey’s findings and known ASD risk genes, which when that overlap was subject to network analysis, we found Pten and Psd-95 to again be prominent nodes (Fig. 5).

The lack of overlap among the –omic datasets, especially the $Pten^{m3m4/m3m4}$ neural proteome and transcriptome, is likely our most surprising finding. Importantly, despite this, we found that they affected final common pathways. As this is the first exploration of a transcriptome and proteome simultaneously in a $Pten$
model, it is difficult to comment whether this finding would be typical. The “knee-jerk” conclusion may be that multiple molecules can feed the same pathway. However, it is edifying to note that in mice, the average correlation between the transcriptome and proteome is modest, 27%, which has been shown to be partially explained by alternative splicing [31]. However, our findings still show less overlap than would be expected based on the aforementioned average. Subsequently, these findings appear to indicate that gene versus protein expression, at least in our model, are regulated by different mechanisms, and perhaps reflecting no need for redundancy. It is possible that dysregulated transcription and splicing factor expression may be responsible in part for changes in gene expression [25,26], whereas translational mechanisms subsequent to changes in the phosphoproteome, including signaling changes downstream of Pten (e.g. dysregulation of translational control from changes in mTOR activity) may be responsible for the changes in protein expression. The possibility of significant changes in translational control in the \( Pten^{m3m4/m3m4} \) brain are real and tantalizing; disruption of proteins involved in translational control, including many in the PI3K/AKT/mTOR cascade, have been recently shown to mediate ASD phenotypes [32]. It is also possible that changes in alternative splicing may affect the differential protein expression that has been observed in the \( Pten^{m3m4/m3m4} \) brain [26]. Furthermore, the lack of overlap between the proteome and phosphoproteome suggests differential modes of regulation at these levels with minimal redundancy. Thus, mechanisms that regulate protein expression appear to be distinct from the mechanisms that regulate phosphorylation the \( Pten^{m3m4} \) brain, and a phenomenon previously observed and described in other models [33]. This differential regulation seems like a reasonable possibility in our model given that it is probable that a portion of the observed changes in the \( Pten^{m3m4/m3m4} \) neural phosphoproteome are more proximal to the dysfunction introduced by the m3m4 mutation than the differential gene/protein expression. This is likely due to the primary functional role of Pten as a dual-specificity phosphatase with possibly a large array of diverse protein substrates [34–42]. Additional biochemical experiments and expanded -omic surveys on this model and other various neural Pten models will be required to disentangle the complexity at the various biological levels.

Beyond the lack of overlap between transcriptome and proteomes, we found the continued emergence of Pten and Psd-95 in the proteome and phosphoproteome pathway and network analysis to be a crucial indicator of their importance to the underlying pathology of the \( Pten^{m3m4/m3m4} \) brain and potentially to ASD in general. This postulate appears to be supported by one of the only two proteomic analyses of post-mortem ASD brains that identified Psd-95 as a major hub protein in the Brodmann area 19 (BA19) [17]. Although their finding was in the proteome, whereas ours was in the phosphoproteome, the shared finding is striking, and it is also possible that the effect of the perturbations to Psd-95 have similar biological effects in both contexts. There were other hits that our study shared with that of Abraham and colleagues (e.g. MAPT), suggesting proteomic approaches to ASD may uncover shared pathological hallmarks.

The picture of the broader changes in the (phospho)proteome of the \( Pten^{m3m4/m3m4} \) brain was largely aligned with our hypotheses, and in many ways, consistent with the overall pathophysiological changes we observed previously in the \( Pten^{m3m4/m3m4} \) neural transcriptome [25]. Although many of the specific molecules and pathways found to be dysregulated or enriched, respectively, are different across the various datasets, there is a convergence on biological pathways downstream of Pten functions and disease processes that manifest in individuals with germline \( PTEN \) mutations, such as neurodevelopmental abnormalities and cancer (Additional file 3). Interestingly, the co-occurrence of neurodevelopmental and cancer pathways arising from study of \( Pten^{m3m4/m3m4} \) brain underscores how closely the biology of these two seemingly disparate disease processes
are and that an important nexus between them is PTEN. Our detailed description of the affected pathways and processes at the (phospho)proteomic levels appear to suggest that there may be convergent mechanisms at play in autism and that the apparent complexity might be reduced to a few central molecules and pathways despite a complex phenotype.

**Limitations**

The $Pten^{m3m4}$ model is excellent for the purposes of this study, but it is quite unique, and our study is limited to this model. Thus, our observations cannot necessarily be extended to all mutations or disruptions of $Pten$ despite some of the evidence here and in the literature that support generalizability. In fact, it is quite likely that at least part of the expression and phosphorylation changes are specific to the m3m4 model due to the homozygosity of the mutation and cytoplasmic predominance of Pten expression – both features that are unique to our model and rarely, if ever, modeled in other studies. Furthermore, our study would have ostensibly been more sensitive to changes in the proteome, phosphoproteome, and transcriptome with a larger sample size. Although the PCA findings cluster $Pten^{m3m4/m3m4}$ and $Pten^{+/+}$ separately, there is still enough variation within each genotype to indicate that our study would likely find more significant hits, if sample size expanded. Subsequently, we have likely only uncovered the most differentially expressed/phosphorylated molecules, but there may remain important subtle changes in major regulators that were missed.

**Conclusions**

In sum, our study represents an important entry into understanding the proteome and phosphoproteome in a $Pten$ model with well described neurological pathologies and behavioral deficits. Given the current lack of knowledge of what the proteomic and phosphoproteomic landscapes should look like in the context PTEN-ASD or even idiopathic ASD, this study is a step toward filling this critical knowledge gap. The observed changes in protein expression and phosphorylation appear to affect pathways and processes important in the nervous system (e.g. neurodevelopment and synaptic function) and neuroinflammation. Despite the shared biological signature across the various -omic datasets, the implicated molecules appear to be distinct, which suggests differential modes of regulation across the different biological tiers and/or the fact that multiple seemingly disparate molecules converge on final common pathways. As such, the molecules that do emerge from our study as major regulatory players, Pten and Psd-95, are strongly associated with autism biology. Our work suggests that a renewed focus on these molecules, specifically developing an understanding that would allow for rescue of their important functions in the nervous system, is critical to tackle the clinical challenges presented by ASD.

**Abbreviations**

ASD: autism spectrum disorder; CNS: central nervous system; PCA: Principal component analysis; PTEN: Phosphatase and Tensin Homolog; (Phospho)proteome: phosphoproteome and proteome; PHTS: PTEN Hamartoma Tumor Syndrome; pS/pT: phospho-serine/phospho-threonine; pY: phospho-tyrosine

**Declarations**

**Acknowledgements**
We are grateful to Qi Yu for helping with mouse breeding and husbandry in the Eng lab, and Peter Bazeley for bioinformatics core support. CE is the Sondra J. and Stephen R. Hardis Endowed Chair of Cancer Genomic Medicine at the Cleveland Clinic, and is an ACS Clinical Research Professor.

**Authors’ contributions**

Conception and design: ST, CE

Experimentation and data acquisition: ST, CE

Interpretation of data: ST, CE

Drafting of manuscript: ST, CE

Critical revisions of manuscript: ST, CE

Final approval of manuscript: ST, CE

**Funding**

This work was funded, in part, by the Zacconi Program of PTEN Research Excellence and the Ambrose Monell Foundation.

**Availability of data and materials**

The datasets for this study are available from the corresponding author on reasonable request.

**Ethics approval**

This study was approved by Cleveland Clinic Lerner Research Institute’s IACUC.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998 May 29;273(22):13375–8.

2. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998 Oct 2;95(1):29–39.

3. Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999 Apr;9(4):125–8.
4. Butler M, Dasouki M, Zhou X, Talebizadeh Z, Brown M, Takahashi T, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet. 2005 Apr;42(4):318–21.

5. Yehia L, Ngeow J, Eng C. PTEN-opathies: from biological insights to evidence-based precision medicine. J Clin Invest. 2019 Feb 1;129(2):452–64.

6. Yehia L, Keel E, Eng C. The Clinical Spectrum of PTEN Mutations. Annu Rev Med. 2020 27;71:103–16.

7. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, et al. Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology. Nature. 2011 May 25;474(7351):380–4.

8. Voineagu I. Gene expression studies in autism: Moving from the genome to the transcriptome and beyond. Neurobiol Dis. 2012 Jan 1;45(1):69–75.

9. Buxbaum JD, Daly MJ, Devlin B, Lehner T, Roeder K, State MW. The Autism Sequencing Consortium: Large scale, high throughput sequencing in autism spectrum disorders. Neuron [Internet]. 2012 Dec 20 [cited 2020 Oct 23];76(6). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863639/

10. Parikshak NN, Swarup V, Belgard TG, Irinia M, Ramaswami G, Gandal MJ, et al. Genome-wide changes in IncRNA, splicing, and regional gene expression patterns in autism. Nature. 2016 Dec;540(7633):423–7.

11. Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science. 2018 Feb 9;359(6376):693–7.

12. He Y, Zhou Y, Ma W, Wang J. An integrated transcriptomic analysis of autism spectrum disorder. Sci Rep. 2019 Aug 14;9(1):1–9.

13. Shnier D, Voineagu MA, Voineagu I. Persistent homology analysis of brain transcriptome data in autism. J R Soc Interface. 2019 Sep 27;16(158):20190531.

14. Breen MS, Browne A, Hoffman GE, Stathopoulos S, Brennand K, Buxbaum JD, et al. Transcriptional signatures of participant-derived neural progenitor cells and neurons implicate altered Wnt signaling in Phelan-McDermid syndrome and autism. Mol Autism. 2020 Jun 19;11(1):53.

15. Junaid MA, Kowal D, Barua M, Pullarkat PS, Sklower Brooks S, Pullarkat RK. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet A. 2004 Nov 15;131(1):11–7.

16. Broek JAC, Brombacher E, Stelzhammer V, Guest PC, Rahmoune H, Bahn S. The need for a comprehensive molecular characterization of autism spectrum disorders. Int J Neuropsychopharmacol. 2014 Apr;17(4):651–73.

17. Abraham JR, Szoko N, Barnard J, Rubin RA, Schlatzer D, Lundberg K, et al. Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes. Sci Rep. 2019 Sep 11;9(1):13118.

18. Abraham J, Szoko N, Natowicz MR. Proteomic Investigations of Autism Spectrum Disorder: Past Findings, Current Challenges, and Future Prospects. Adv Exp Med Biol. 2019;1118:235–52.

19. Szoko N, McShane AJ, Natowicz MR. Proteomic explorations of autism spectrum disorder. Autism Res Off J Int Soc Autism Res. 2017 Sep;10(9):1460–9.

20. Chung J-H, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res. 2005 Sep 15;65(18):8096–100.
21. Tilot AK, Gaugler MK, Yu Q, Romigh T, Yu W, Miller RH, et al. Germline disruption of Pten localization causes enhanced sex-dependent social motivation and increased glial production. Hum Mol Genet. 2014 Jun 15;23(12):3212–27.

22. Lee H, Thacker S, Sarn N, Dutta R, Eng C. Constitutional mislocalization of Pten drives precocious maturation in oligodendrocytes and aberrant myelination in model of autism spectrum disorder. Transl Psychiatry. 2019 Jan 17;9(1):13.

23. Sarn N, Jaini R, Thacker S, Lee H, Dutta R, Eng C. Cytoplasmic-predominant Pten increases microglial activation and synaptic pruning in a murine model with autism-like phenotype. Mol Psychiatry. 2020 Feb 13;

24. Kang SC, Jaini R, Hitomi M, Lee H, Sarn N, Thacker S, et al. Decreased nuclear Pten in neural stem cells contributes to deficits in neuronal maturation. Mol Autism. 2020 Jun 1;11(1):43.

25. Tilot AK, Bebek G, Niazi F, Altemus J, Romigh T, Frazier TW, et al. Neural transcriptome of constitutional Pten dysfunction in mice and its relevance to human idiopathic Autism Spectrum Disorder. Mol Psychiatry. 2016 Jan;21(1):118–25.

26. Thacker S, Sefyi M, Eng C. Alternative splicing landscape of the neural transcriptome in a cytoplasmic-predominant Pten expression murine model of autism-like Behavior. Transl Psychiatry. 2020 Nov 6;10(1):380.

27. Irimia M, Weatheritt RJ, Ellis J, Parikshak NN, Gonatopoulos-Pournatzis T, Babor M, et al. A highly conserved program of neuronal microexons is misregulated in autistic brains. Cell. 2014 Dec 18;159(7):1511–23.

28. Fricano-Kugler CJ, Getz SA, Williams MR, Zurawel AA, DeSpenza T, Frazel PW, et al. Nuclear Excluded Autism-Associated Phosphatase and Tensin Homolog Mutations Dysregulate Neuronal Growth. Biol Psychiatry. 2018 15;84(4):265–77.

29. Frazier TW, Embacher R, Tilot AK, Koenig K, Mester J, Eng C. Molecular and Phenotypic Abnormalities in Individuals with Germline Heterozygous PTEN Mutations and Autism. Mol Psychiatry. 2015 Sep;20(9):1132–8.

30. Jurado S, Benoist M, Lario A, Knafo S, Petrok CN, Esteban JA. PTEN is recruited to the postsynaptic terminal for NMDA receptor-dependent long-term depression. EMBO J. 2010 Aug 18;29(16):2827–40.

31. Ghazalpour A, Bennett B, Petyuk VA, Orozco L, Hagopian R, Mungrue IN, et al. Comparative Analysis of Proteome and Transcriptome Variation in Mouse. PLoS Genet [Internet]. 2011 Jun 9 [cited 2020 Oct 30];7(6). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111477/

32. Hooshmandi M, Wong C, Khoutorsky A. Dysregulation of translational control signaling in autism spectrum disorders. Cell Signal. 2020 Nov;75:109746.

33. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng. 2009;11:49–79.

34. Crockett DK, Fillmore GC, Elenitoba-Johnson KSJ, Lim MS. Analysis of phosphatase and tensin homolog tumor suppressor interacting proteins by in vitro and in silico proteomics. Proteomics. 2005 Apr;5(5):1250–62.

35. Herlevsen M, Oxford G, Ptak C, Shabanowitz J, Hunt DF, Conaway M, et al. A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer. Biochem Biophys Res Commun. 2007 Jan 12;352(2):549–55.
36. Ahn Y, Hwang CY, Lee S-R, Kwon K-S, Lee C. The tumour suppressor PTEN mediates a negative regulation of the E3 ubiquitin-protein ligase Nedd4. Biochem J. 2008 Jun 1;412(2):331–8.

37. Gorbenko O, Panayotou G, Zhyvoloup A, Volkova D, Gout I, Filonenko V. Identification of novel PTEN-binding partners: PTEN interaction with fatty acid binding protein FABP4. Mol Cell Biochem. 2010 Apr;337(1–2):299–305.

38. Gunaratne J, Goh MX, Swa HLF, Lee FY, Sanford E, Wong LM, et al. Protein Interactions of Phosphatase and Tensin Homologue (PTEN) and Its Cancer-associated G20E Mutant Compared by Using Stable Isotope Labeling by Amino Acids in Cell Culture-based Parallel Affinity Purification. J Biol Chem. 2011 May 20;286(20):18093–103.

39. Maddika S, Kavela S, Rani N, Palicharla VR, Pokorny JL, Sarkaria JN, et al. WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol. 2011 Jun;13(6):728–33.

40. Shnitsar I, Bashkurov M, Masson GR, Ogunjimi AA, Mosessian S, Cabeza EA, et al. PTEN regulates cilia through Dishevelled. Nat Commun. 2015 Sep 24;6:8388.

41. Verrastro I, Tveen-Jensen K, Spickett CM, Pitt AR. The effect of HOCl-induced modifications on phosphatase and tensin homologue (PTEN) structure and function. Free Radic Res. 2018 Feb;52(2):232–47.

42. Smith SL, Pitt AR, Spickett CM. Approaches to Investigating the Protein Interactome of PTEN. J Proteome Res. 2020 Oct 19;

Tables

Table 1. Summary of differentially expressed/phosphorylated molecules identified in the –omic datasets describing the Ptenm3m4 brain.

|                  | P14 Proteome | P40 Proteome | P14 pS/pT Scan | P40 pS/pT Scan | P14 pY Scan | P40 pY Scan | P14 Transcriptome | P40 Transcriptome |
|------------------|--------------|--------------|----------------|----------------|-------------|-------------|-------------------|-------------------|
| Up               | 24           | 49           | 1              | 113            | 31          | 29          | 74                | 832               |
| Down             | 27           | 102          | 99             | 185            | 29          | 26          | 15                | 458               |
| Total            | 51           | 151          | 100            | 298            | 60          | 55          | 89                | 1290              |
| Total Unique Molecules | 51           | 151          | 84             | 235            | 52          | 52          | 89                | 1290              |